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Microsomal triglyceride transfer protein (MTP) 
is a mainly ER-resident 97-kD lipid transfer 
protein that, when complexed with protein 
  disulfi  de isomerase (PDI), transfers lipids to apo-
lipoprotein B (apoB) for the production of very 
low density lipoprotein (VLDL) from hepato-
cytes or chylomicrons from intestinal epithelial 
cells (IECs) (1–3). MTP transfers phospho-
lipids, triglycerides, and cholesterol to nascent 
apoB during its translocation into the ER. 
Kinetic studies of MTP-mediated transfer of vari-
ous lipid classes revealed that MTP has at least 
two lipid transfer sites: a fast site that transfers 
triglycerides and cholesterol esters and a slow 
site that transfers phospholipids (2, 3). Although 
apoB-containing lipoproteins are largely com-
posed of triglycerides, drosophila MTP, which 
cannot transfer triglycerides but can transfer 
phospholipids, can support apoB secretion (4). 
This fi  nding demonstrates that the phospho-
lipid transfer function of MTP is suffi   cient for 
apoB secretion. MTP is highly abundant in 
hepatocytes and IECs and has been found, along 
with modest apoB secretion, in cardiac myo-
cytes, retina, and placenta (5–8). MTP deletion 
is embryonic lethal in mice, presumably be-
cause of insuffi   cient lipid nutrient transfer from 
the placenta (9, 10). Humans homozygous for 
mutations in MTP develop abetalipoproteine-
mia, a disease characterized by malabsorption 
of lipids and lipophilic vitamins (11).
NKT cells are positively selected by CD1d 
on CD4+CD8+ thymocytes (12). Negative 
  selection can also occur, as shown by deletion 
of NKT cells in fetal thymic organ cultures 
(FTOCs) treated with the potent agonist 
α-  galactosylceramide (α-galcer); negative selec-
tion is mediated largely by thymus-resident 
DCs, but negative selection by CD4+CD8+ 
cells may also occur (13–17). NKT cells develop 
in mice that have CD1d expression restricted 
to T lineage cells, indicating that thymocyte 
expression of CD1d is suffi   cient for NKT de-
velopment (18, 19).
Endogenous lipids, derived from both the 
ER and the endosomal compartment, likely 
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Microsomal triglyceride transfer protein (MTP), an endoplasmic reticulum lipid transfer 
protein critical for apolipoprotein B (apoB) secretion, regulates CD1d antigen presentation. 
We identifi  ed MTP variant 1 (MTPv1), a novel splice variant of mouse MTP, by polymerase 
chain reaction and Northern analysis in non–apoB-secreting tissues, including thymocytes 
and antigen-presenting cells (APCs). Edman degradation of MTPv1 isolated from trans-
fected cells revealed three unique residues; however, recombinant MTP and MTPv1 had an 
equivalent protein disulfi  de isomerase association, subcellular localization, triglyceride 
transfer, phospholipid transfer, response to inhibitors, and ability to support apoB secretion. 
MTP and MTPv1 effi  ciently transferred phosphatidylethanolamine to CD1d in vitro. NKT cells 
fail to develop in fetal thymic organ culture (FTOC) treated with MTP antagonists. MTP-
inhibited FTOCs produced negligible numbers of CD1d tetramer–positive cells and exhibited 
marked defects in IL-4 production upon stimulation with anti-CD3 or 𝗂-galactosylceramide–
pulsed APCs. CD1d expression on CD4+CD8+ FTOC cells was unaffected by MTP inhibition. 
Thus, our results demonstrate that MTPv1 in thymocytes is critical to NKT cell develop-
ment. We hypothesize that, when MTP is inactive, CD1d traffi  cs to the cell surface and 
presents no lipid or a lipid that is incapable of mediating NKT cell selection and/or is 
  refractory to lysosomal editing.
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play a role in NKT cell selection. Phosphatidylinostitol and 
phosphatidylcholine, presumably of ER origin, have been 
found associated with CD1d, and at least one phosphati-
dylinositol-reactive NKT cell hybridoma has been character-
ized (20–22). The vesicular traffi   cking protein AP-3 transports 
CD1d from the cell surface to the endosomal/lysosomal 
compartment. Lysosomal saposins, generated by cathepsin 
L–mediated cleavage of prosaposin, and GM2 activator pro-
tein can exchange ER-derived lipids bound by CD1d for 
  lysosomal lipids such as iGb3. Loss of AP-3, prosaposin, or 
cathepsins L or S; decreased production of iGb3 caused by 
β-hexosaminidase B defi  ciency; or altered lipid storage caused 
by loss of Niemann-Pick type C1 all result in impaired NKT 
cell development (23–29). ER and endosomal lipids diff  er in 
their potential to select NKT cells; a tail-deleted form of 
CD1d, which remains at the cell surface and fails to traffi   c to 
endosomes, can activate NKT hybridomas with diverse, but 
not invariant, TCRs and exclusively supports development of 
diverse NKT cells (30, 31).
MTP has been shown to regulate CD1d antigen presen-
tation in vitro and in vivo (32, 33). These previous studies 
found MTP mRNA, protein, and activity in multiple mouse 
and human tissues, including APCs. Silencing and chemical 
inhibition of MTP in APCs caused a selective defect in CD1d 
presentation. Furthermore, purifi  ed MTP directly transfers 
phospholipid to recombinant CD1d in vitro (33). In the cur-
rent studies, we report that mouse hematopoietic cells   express 
a novel isoform of MTP, which accounts for ubiquitous low 
level expression of MTP. We further explore the role of 
MTP in NKT cell development using FTOC and show that 
MTP lipid transfer activity is required for production of invari  ant 
NKT cells.
RESULTS
Mouse MTP is regulated by alternate splicing
Previous work from our laboratory made use of the MTPMx1 
mouse to demonstrate the role of MTP in CD1d presentation 
on hepatocytes and IECs (32). This mouse, which contains 
loxp sites fl  anking the promoter and exon 1 of the mttp gene, 
undergoes Cre-mediated deletion upon injection with the 
TLR3 ligand, polyinosinic-polycytidylic acid (34). Deletion 
is highly effi   cient in the liver, resulting in the loss of MTP-
mediated lipidation of apoB and, consequently, loss of VLDL 
secretion and low serum triglycerides (34). The MTPMx1 
Figure 1.  Mouse MTP in thymocytes is transcribed from an alter-
nate promoter. (A) 5′ RACE was performed on cDNA from MTPlck thymo-
cytes. mttp from Lck-Cre (Lck) thymocytes is shown as a positive control. 
The resulting bands were excised, cloned, and sequenced. (B) Diagram of 
mttp and mttp_v1 coding regions.
Table I.  Summary of sequencing of MTP 5′ RACE products
Tissue Transcript Number of clones
Thymus (wild type) mttp_v1 1
Thymus (MTPlck) mttp_v1 2
L cells mttp_v1 1
DN32 mttp_v1 1
Flt3L splenocytes mttp_v1 1
BM-derived DCs mttp_v1 2
Hepatocytes mttp 3
aEyeball mttp_v1 NCBI (gi:74200200)
aRecently reported and available from GenBank/EMBL/DDBJ under accession no. 
74200200.JEM VOL. 204, March 19, 2007  535
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mouse has therefore been used as a model for lipoprotein dis-
orders (35, 36).
The Mx1 promoter displays low activity in the thymus 
(37). Therefore, in an attempt to parse out the role of MTP 
in thymic selection of NKT cells, we intercrossed the MTP-
fl  oxed mouse to an Lck-Cre mouse that has Cre expression 
driven by the proximal Lck promoter. The resulting MTPlck 
mice had >95% deletion of mttp at the genomic level (unpub-
lished data) but showed no decrease in mttp transcription. We 
amplifi  ed and sequenced full-length cDNAs from wild-type 
and MTPlck thymi using 5′ and 3′ rapid amplifi  cation of 
cDNA ends (RACE), and identifi  ed a novel splice variant of 
MTP (Fig. 1 A). This alternate transcript of mttp (mttp_v1) 
makes use of an alternate exon 1 (exon v1) with a predicted 
start codon 2.6 kb upstream of the previously characterized 
start site. Based on sequence analysis of 5′ RACE products, 
exon v1 splices directly in frame with exon 2, skipping exon 1 
(Fig. 1 B). Deletion of mttp exon 1 in the MTPMx1 or MTP-
lck mouse therefore does not aff  ect transcription of mttp_v1.
We sequenced full-length mttp cDNAs from a variety of 
other tissues, including DCs (splenic and BM-derived), the 
DN32 NKT hybridoma, and a fi  broblast line (Table I). In 
each of these tissues, we found the mttp_v1 transcript. As a 
positive control, mouse hepatocytes contained the previously 
described mttp transcript.
mttp and mttp_v1 differ in their abundance 
and tissue distribution
To analyze the tissue distribution of mttp and mttp_v1, we 
performed semiquantitative RT-PCR on cDNA dilutions 
Figure 2.  mttp and mttp_v1 differ in their tissue distribution. 
(A) RT-PCR was performed using cDNA synthesized from 1 μg of total 
RNA from the indicated tissues and cell lines. Panels show that RT-PCR 
products from cDNA used neat, 1:10 and 1:100 dilutions. MTT1/2 primers 
  amplify total MTP transcripts; mttp_v1 exon 1 and mttp exon 1 primers 
amplify mttp_v1 and mttp, respectively. All RT-PCR for MTP used the 
same reverse primer (MTT2). RT-PCR for β-actin is shown as a loading 
control. Flt3L spleen indicates splenocytes from a mouse treated with 
Flt3L-secreting melanoma to increase numbers of splenic DCs; RMAS 
represents the mouse thymoma line; 24.8 indicates mouse autoreactive 
NKT hybridoma; RAW represents the mouse macrophage line; MODE-K 
indicates the mouse IEC line; and L cells represent the mouse fi  broblast 
line. (B) Northern blot analysis was performed on total RNA from the 
indicated tissues. Each sample was run in triplicate, and identical blots 
were hybridized with probes corresponding to total MTP (mttp exons 9–13), 
mttp (exon 1), mttp_v1 (exon v1), or β-actin. DN32 indicates the 
mouse invariant NKT hybridoma. Blots were exposed to film for 8 h 
(left and middle) or 24 h (right). (C) Wild-type splenocytes were sorted 
using magnetic bead separation. Semiquantitative RT-PCR was performed 
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from a panel of tissues and cell lines using primers that ampli-
fi  ed mttp, mttp_v1, or both (MTT1/2). mttp_v1 was ubiqui-
tously expressed, including the small intestine and hepatocytes, 
whereas mttp expression was restricted to the intestine, the 
liver, and the NKT cell hybridoma 24.8 (Fig. 2 A). mttp_v1 
expression in intestine and hepatocyte samples may have re-
sulted from contaminating leukocytes in these preparations; 
however, an IEC line, MODE_K, expressed mttp_v1, suggesting 
that IECs themselves are capable of transcribing mttp_v1, albeit 
at substantially lower levels than mttp.
To confi  rm the RT-PCR data, we performed Northern blot 
analysis on RNA from the intestine, liver, DCs (Flt3L spleen), 
and an NKT hybridoma using probes specifi  c for mttp, mttp_v1, or 
a downstream portion of the MTP gene common to both tran-
scripts (mttp probe exons 9–13). Although MTP transcripts are 
clearly present in all four tissues, mttp was expressed predominantly 
Figure 3.  Mouse and human MTP exhibit different mechanisms of 
transcriptional regulation. (A) Wild-type mouse splenocytes were stim-
ulated for 24 h with the indicated compounds. Total RNA was harvested, 
and 1 μg was used for cDNA synthesis. MTP (left) and IL-2 (right) tran-
script levels were quantifi  ed by real-time PCR and adjusted to 18S rRNA 
levels. Both mttp and mttp_v1 are amplifi  ed in this assay. (B) Human 
PBMCs were stimulated for 1, 3, or 5 d with the indicated mitogens. MTP 
(left) and IL-2 (right) transcript levels were quantifi  ed by real-time PCR as 
in A. (C) Human PBMCs stimulated for 3 d with the indicated mitogens 
were stained with anti-CD3 and anti-CD69 and analyzed by fl  ow cytom-
etry. (D) HepG2 cells and human PBMCs were stimulated for 3 d with the 
indicated compounds. MTP transcript levels, quantifi  ed by real-time PCR 
as in A, are shown as the fold change compared with unstimulated cells. 
Values are ±SD.JEM VOL. 204, March 19, 2007  537
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in intestine and liver, whereas mttp_v1 accounted for the MTP 
expression in DCs and NKT cells (Fig. 2 B).
We further analyzed mttp and mttp_v1 expression in sorted 
splenic populations. mttp_v1 was detected in all populations, 
but we were unable to detect mttp (Fig. 2 C and not 
  depicted). We therefore conclude that mttp_v1 is the major, 
and perhaps the only, transcript encoding MTP in mouse 
  hematopoietic cells.
MTP transcription is differentially regulated in the mouse 
and human
To assess the regulation of mttp_v1 transcription, we stimu-
lated whole-mouse splenocytes with a panel of mitogens and 
TLR ligands and examined mttp_v1 expression by quantita-
tive real-time PCR (Fig. 3 A). Although IL-2 transcription 
and CD69 surface expression were up-regulated in each case 
(Fig. 3 A and not depicted), no changes in mttp_v1 expression 
were observed.
We next determined whether human tissues also show 
alternate splicing. Sequencing of mtp from monocyte-derived 
DCs, PBMCs, or a B cell lymphoma line revealed transcripts 
corresponding to the previously published sequence from 
human liver (38), indicating that human MTP is not regu-
lated by alternate splicing (unpublished data). When human 
PBMCs were stimulated with a panel of mitogens, mtp tran-
scription was up-regulated (Fig. 3 B), which is in contrast to 
observations in mouse splenocytes (Fig. 3 A). PBMC activa-
tion was confi  rmed by increased IL-2 production (Fig. 3 B) 
and surface CD69 expression (Fig. 3 C).
HepG2 is a human hepatoma cell line known to express 
MTP (39). HepG2 cells express 300-fold more mtp transcripts 
than PBMCs (unpublished data). When PBMCs and HepG2 
cells were stimulated in parallel with PHA, PMA, and iono-
mycin (ION), or pokeweed mitogen, mtp transcription was 
up-regulated in PBMCs. In contrast, mtp was unchanged or 
down-regulated in HepG2 cells (Fig. 3 D). Insulin treatment, 
which is known to down-regulate mtp in HepG2 cells (39), 
decreased mtp transcription in HepG2 cells but had no eff  ect 
on mtp transcription in PBMCs (Fig. 3 D).
MTP and MTP variant 1 (MTPv1) proteins 
are functionally equivalent
The amino acid sequence encoded by mttp_v1 suggested the 
presence of a signal peptide. To determine the exact signal 
peptidase cleavage site, we transduced Ld cells with a retro-
virus encoding MTPv1 tagged at the C terminus with the 
FLAG epitope (MTPv1-FLAG). We purifi  ed MTPv1-FLAG 
by immunoprecipitation and observed that it associated with 
a 55-kD protein, presumably PDI, the “P” subunit of the 
microsomal triglyceride transfer complex (Fig. 4 A). We 
  excised the 97-kD band corresponding to MTP and determined 
the N-terminal sequence by Edman degradation. These stud-
ies show that signal peptidase cleaves MTPv1 between residues 
21 and 22, generating three novel amino acids (asn-ser-gly) in 
the mature protein that are not present in the original MTP 
sequence (Fig. 1 B).
Although the N terminus of MTP is not part of a previ-
ously described functional domain, we investigated whether 
the addition of asn-ser-gly resulted in a functional diff  erence 
between MTP and MTPv1. To this end, we generated retro-
viruses encoding MTP, MTPv1, MTP-FLAG, and MTPv1-
FLAG. The FLAG tag was used for immunofl  uorescence or 
when purifi  cation of MTP was required; the untagged ver-
sions of MTP were used when whole cells or whole cell 
  lysates would suffi   ce. No diff  erences in lipid transfer activity 
were observed between tagged and untagged MTP, either in 
the current study or in a previously published work (4).
Both forms of mouse MTP associated with PDI. Coo-
massie blue staining revealed equal amounts of the 55-kD 
“P” subunit coprecipitating with MTP-FLAG and MTPv1-
FLAG (Fig. 4 A), and immunofl  uorescent staining of Ld cell 
transductants showed colocalization of MTP-FLAG and 
MTPv1-FLAG with PDI (Fig. 4 B). Furthermore, both iso-
forms of MTP were ER localized, as demonstrated by co-
localization of MTP-FLAG and MTPv1-FLAG with the ER 
marker calnexin (Fig. 4 B).
We next addressed the lipid transfer function of MTP 
  using a fl  uorescence-based assay (40, 41). MTP and MTPv1 
were equally effi   cient at transferring triglyceride, as shown 
using whole cell lysates from transduced Ld cells (Fig. 4 C) or 
purifi   ed MTP-FLAG and MTPv1-FLAG (not depicted). 
Both isoforms of purifi  ed FLAG-tagged MTP were equally 
effi   cient at transferring phospholipid (Fig. 4 D). The trigly-
ceride transfer and phospholipid transfer functions of MTPv1 
could be inhibited by several chemical inhibitors of MTP, 
including BMS212122, BMS200150, and CP346086 (Fig. 
S1, available at http://www.jem.org/cgi/content/full/jem
.20062006/DC1; and not depicted). Thus, MTPv1 lipid 
transfer is sensitive to at least some of the same compounds 
that block MTP activity. This is of particular importance 
  because BMS212122 and the control compound 9-fl  uoronyl 
carboxylic acid (9-FL) were previously used to demonstrate 
the functional role of MTP in CD1d antigen presentation in 
APCs (31), and we now show that MTPv1 is the relevant 
form of MTP in these cells.
The major function of MTP in the liver and intestine is 
to transfer lipid to apoB. Therefore, we investigated whether 
MTPv1 could lipidate apoB. Using either Ld cells or COS 
cells stably transduced with MTP or MTPv1 and transiently 
transfected with apoB48, we found that both isoforms of 
MTP supported apoB secretion (Fig. 4 E). Although COS 
cells produced more apoB than Ld cells, no diff  erence in 
apoB secretion could be observed between MTP- and MTPv1-
transduced cells.
MTP-mediated transfer is the rate-limiting step in apoB 
secretion; studies show that production of buoyant apoB par-
ticles in cell culture and serum lipoprotein levels in vivo are 
positively correlated with MTP activity (42, 43). In contrast, 
MTP is not rate limiting for CD1d presentation, and trace 
amounts of MTP have been shown to be suffi   cient for maxi-
mal CD1d presentation in hematopoietic cells (33). In addi-
tion, the low endogenous levels of MTPv1 in commonly used 538  MTPV1 IN NKT CELL DEVELOPMENT | Dougan et al.
CD1d-transfected hematopoietic and epithelial cell lines (e.g., 
C1R, HELa, or L cells) are capable of supporting high level 
CD1d expression. Ld MTP and Ld MTPv1 are fi  broblast lines 
transfected with CD1d and transduced with MTP-FLAG and 
MTPv1-FLAG. The parent cell line, Ld, expresses MTPv1 
(Fig. 2 A) and requires MTPv1 activity for antigen presentation 
Figure 4.  MTP and MTPv1 proteins are functionally equivalent. 
(A) Lysates from Ld cells transduced with MTP-FLAG or MTPv1-FLAG were 
immunoprecipitated with M2 resin. FLAG peptide–eluted fractions were sub-
jected to SDS-PAGE and stained with Coomassie blue. (B) Confocal images 
were taken of Ld cells transduced with MTPv1-FLAG (top) or MTP-FLAG 
(bottom) and stained with M2 anti-FLAG and either anti-calnexin (right) or 
anti-PDI (left). Bar, 20 μm. (C) Lysates from Ld cells transduced with MTP or 
MTPv1 were normalized to contain equal amounts of MTP protein, as deter-
mined by immunoblot, and compared with lysates from untransduced Ld 
cells. Transfer of NBD-triglycerides to unlabeled acceptor vesicles is shown. 
(D) MTP-FLAG and MTPv1-FLAG were purifi  ed from transduced Ld cells, and 
0.1 μg of purifi  ed protein was used per replicate. Transfer of NBD-PE to un-
labeled acceptor vesicles is shown. (E) Ld and COS-7 cells untransduced and 
transduced with MTP or MTPv1 were transiently transfected with apoB48. 
Secretion of apoB48 was measured by ELISA of culture supernatants. (F) Ld 
cells were cultured in media containing vehicle or 13 μM BMS212122 for 5 d, 
harvested, fi  xed with glutaraldehyde, and washed before co-culture with 
80,000 24.8 NKT cells. IL-2 was measured by ELISA of 24-h culture superna-
tants. (G) Ld untransduced cells and Ld cells transduced with MTP-FLAG or 
MTPv1-FLAG were cultured with 20,000 24.8 NKT cells (left) or pulsed with 
α-galcer for 6 h, washed, and cultured with 20,000 DN32 NKT cells (right). 
IL-2 was measured by ELISA of 24-h culture supernatants. Values are ±SD. JEM VOL. 204, March 19, 2007  539
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on CD1d (Fig. 4 F). Although BMS212122 inhibition of 
MTP diminishes CD1d presentation in Ld cells, transduction 
of Ld cells with MTP or MTPv1 does not enhance CD1d 
presentation (Fig. 4, F and G). Ld, Ld MTP, and Ld MTPv1 
stimulate the autoreactive NKT hybridoma 24.8 and present 
α-galcer to the NKT hybridoma DN32 with equal effi   ciency 
(Fig. 4 G). Overexpression of MTP did not confer any added 
benefi  t to CD1d presentation, confi  rming the hypothesis that 
MTP is not rate limiting for CD1d expression.
MTP and MTPv1 directly transfer phospholipid to mouse 
and human CD1d
We previously reported that MTP purifi  ed from rat liver 
could transfer fl   uorescently labeled phosphatidylethanol-
amine (PE) to immobilized mouse CD1d in vitro (33). Using 
the same in vitro lipid transfer assay, we found that MTP-
FLAG and MTPv1-FLAG lipidate CD1d with equal effi   ciency, 
indicating that the relevant form of MTP in APCs is capable 
of transferring phospholipid to CD1d (Fig. 5). Mouse CD1d, 
both from a baculovirus expression system (Fig. 5 A) and as 
an Fc fusion protein (Fig. 5 B), accepted MTP-transferred 
phospholipid. When 7-nitro-2,1,3-benzoxadiazol-4-yl (NBD)–
labeled triglyceride, which does not fi   t into the CD1d 
groove, was used in place of NBD-PE, no transfer of fl  uores-
cence to CD1d was observed (Fig. 5 A). As further evidence 
of the specifi   city of transfer to CD1d, MTP-FLAG and 
MTPv1-FLAG did not transfer phospholipid to immobilized 
MHC class I (Fig. 5 B). These data strongly indicate that 
MTP and MTPv1 load phospholipid into the CD1d antigen-
binding groove. Of note, mouse MTP and MTPv1 also 
transferred phospholipid to human CD1d (Fig. 4 C). Given 
the 85% identity between mouse and human MTP and the 
fact that human NKT cells can recognize mouse CD1d and 
vice versa, this result is perhaps not surprising (44). Overall, 
we found that MTP lipidation of CD1d is robust, reproducible, 
and displays cross-species activity.
MTP activity is critical for NKT cell development
Thymocytes exclusively express the mttp_v1 transcript of 
MTP; thus, only this isoform is available to lipidate CD1d 
(Table I and Fig. 2 A). This is of particular importance given 
that CD1d-bearing thymocytes are responsible for NKT cell 
selection. The currently available MTP conditional knock-
out mice delete mttp exon 1 but retain expression of mttp_v1; 
thus, thymic MTP expression is not diminished in these mice 
(Fig. 1 A). To address the role of MTP in NKT cell selec-
tion, we examined FTOC. NKT cells develop after pro-
longed culture of fetal thymic lobes  (14, 16), and our 
preliminary experiments showed that embryonic day 16 thy-
mic lobes cultured for 18 d produced the maximal yield of 
NKT cells, as defi   ned by staining with α-galcer–loaded 
CD1d tetramer (unpublished data).
FTOCs treated with either BMS212122 or BMS200150 
exhibited a profound defect in NKT cell development (Figs. 
6, A and B). Although the percent yield of CD1d tetramer–
positive NKT cells that developed in vehicle-treated or 
9-FL–treated cultures was somewhat variable, we were unable to 
detect NKT cells by tetramer staining in either MTP-inhibited 
culture in six independent replicates (Fig. 6 B). Because non-
invariant NKT cells or invariant NKT cells that have down-
regulated their TCRs would not be detected by tetramer 
Figure 5.  MTP and MTPv1 directly transfer phospholipid to CD1d 
in vitro. (A) 2 μg BSA or recombinant mouse CD1d, produced in a bacu-
lovirus expression system, were coated onto a microtiter plate. Vesicles 
containing NBD-labeled PE or triglyceride were added with 0.1 μg of 
purifi  ed MTP-FLAG or MTPv1-FLAG, as indicated, for 2.5 h. After washing, 
isopropanol was added to each well, and the total fl  uorescence was 
measured. Values shown are total fluorescence minus background. 
*, P < 0.05; and **, P < 0.01 versus no MTP. (B) Lipid transfer assays were per-
formed as in A except that microtiter wells were coated with protein G, 
protein G plus mouse CD1d-Fc, or protein G plus mouse MHC I-Fc. 
*, P < 0.05 versus transfer to protein G and P < 0.005 versus transfer to 
MHCI-Fc. (C) Lipid transfer assays were performed as in A, except that 
microtiter wells were coated with protein G or protein G plus human 
CD1d-Fc. *, P < 0.002 versus no MTP. Values are ±SD.540  MTPV1 IN NKT CELL DEVELOPMENT | Dougan et al.
staining, we also looked for the functional presence of NKT 
cells. FTOC cells stimulated with plate-bound anti-CD3 
produce IL-4, which is largely attributable to NKT cells (16). 
To verify that IL-4 production in this system is caused by the 
presence of NKT cells, FTOC cells from CD1d−/− thymic 
lobes were stimulated with anti-CD3. CD1d−/− FTOC cells 
produced less than half as much IL-4 as anti-CD3–stimulated 
wild-type FTOC cells, thus ascribing the production of IL-4 
mainly to NKT cells in this assay (Fig. 6 C). Likewise, MTP-
inhibited FTOC cells displayed a profound defect in IL-4 
production, indicating the lack of NKT cells in these cultures 
(Fig. 6 C). Finally, MTP-inhibited FTOC cells failed to pro-
duce IL-4 in response to α-galcer–pulsed CD1d transfectants, 
demonstrating a specifi  c loss of α-galcer–reactive NKT cells 
(Fig. 6 C).
To investigate nonspecifi  c eff  ects of the MTP inhibitor 
compounds in FTOCs, CD4 and CD8 T cell development 
was also analyzed. Although cultures treated with BMS200150 
or 9-FL were indistinguishable from vehicle-treated cultures, 
BMS212122 aff  ected CD4 and CD8 T cell development such 
that fewer double-positive and more single-positive T cells 
were observed (Fig. 6 D and Fig. S2, available at http://www
.jem.org/cgi/content/full/jem.20062006/DC1). BMS212122 
also caused a modest decrease in surface CD1d expression in 
some, but not all, experimental replicates (Table II and Fig. 
S2). The eff  ect of BMS212122 on T cell development was 
unrelated to the role of MTP on NKT cells in these cultures 
for the following reasons: the MTP inhibitor BMS200150 did 
not aff  ect T cell development, and the eff  ect of BMS212122 
was observed in both wild-type and CD1d-defi  cient mice 
(Table III and Fig. 6 D). Table III shows the average CD4 and 
CD8 T cell yields from six independent FTOCs. BMS212122 
showed a statistically signifi  cant alteration in CD4 and CD8 
T cell development; BMS200150 and 9-FL did not.
The lack of NKT cells in MTP-inhibited FTOCs cannot 
also be attributed to loss of surface CD1d available for selection. 
Figure 6.  Inhibition of MTP in FTOC abrogates NKT cell development. 
(A) Embryonic day 16.5 fetal thymic lobes from wild-type embryos 
were cultured for 18 d in media containing vehicle (DMSO), 13 μM MTP 
inhibitor BMS212122, 10 μM MTP inhibitor BMS200150, or 13 μM of the 
inactive compound 9-FL. FTOC cells were harvested, stained for NKT cells 
using anti-CD3 and α-galcer–loaded CD1d tetramer, and analyzed by fl  ow 
cytometry. FTOC cells from CD1d−/− fetal thymic lobes are shown as a 
negative control. Results are representative of six independent experi-
ments, and percentages indicate CD3+ CD1d tetramer–positive NKT cells. 
(B) Quantifi  cation of NKT cell yields from six independent FTOC experi-
ments, as in A. Horizontal lines represent the means. *, P < 0.02. (C) FTOC 
cells from wild-type fetal thymic lobes cultured with the indicated com-
pounds were stimulated with plate-bound anti-CD3 (left) or CD1d-transfected 
RMAS cells pulsed with α-galcer (right). FTOC cells from CD1d−/− fetal 
thymic lobes are shown as a negative control. IL-4 concentration was 
measured by ELISA of 48-h culture supernatants. *, P = 0.01 versus DMSO 
and P = 0.1 versus 9-FL; **, P < 0.01. ND, not detectable. Values are ±SD. 
(D) Embryonic day 16.5 fetal thymic lobes from CD1d−/− embryos were 
cultured as in A. FTOC cells were harvested, stained with αCD4 and αCD8, 
and analyzed by fl  ow cytometry.JEM VOL. 204, March 19, 2007  541
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Table II shows the median fl  uorescence intensity (MFI) of 
total and double-positive (CD4+CD8+) FTOC cells aver-
aged from four independent experiments. The MTP inhibi-
tor BMS200150 caused no alterations in CD1d surface 
expression on double-positive cells nor any of the other thy-
mic subsets (Fig. S2). Thus, MTP-inhibited FTOCs produce 
normal numbers of double-positive cells expressing normal 
surface levels of CD1d; yet, without MTP function, NKT 
cells fail to develop.
D  I  S  C  U  S  S  I  O  N 
In this paper, we report the discovery of mttp_v1, an alternate 
transcript of mouse mttp, and show that mttp_v1 is the major 
transcript in hematopoietic cells. The protein MTPv1 contains 
three novel amino acids but is functionally identical to MTP. 
Importantly, MTPv1 localizes to the ER and can transfer 
phospholipid to CD1d in vitro, which is consistent with its 
role as a chaperone and lipid transfer protein for CD1d. In 
thymocytes, MTP lipid transfer is required for NKT cell de-
velopment; MTP inhibition in FTOC results in a complete 
loss of NKT cells.
Very little MTP protein is required to support CD1d an-
tigen presentation (33). Low level ubiquitous expression of 
MTP in a wide range of CD1d-positive tissues seems ideal 
for supporting CD1d antigen presentation, and this is exactly 
the distribution pattern observed for mttp_v1. On the other 
hand, MTP is rate limiting for apoB secretion, and produc-
tion of chylomicrons and VLDL is dependent on a large sup-
ply of MTP (42, 43). The discovery that MTP is regulated by 
transcription of mttp_v1 in virtually all tissues, including he-
matopoietic cells, whereas transcription of mttp is mainly de-
tected in apoB-secreting tissues, provides a possible mechanism 
for regulating the dual roles of MTP.
Peroxisome proliferator–activated receptor α binds to a 
DR-1 site in the mttp promoter and is a known transcrip-
tional activator of mttp in hepatocytes (45). Analysis of the 
1,000 base pairs upstream of exon v1 showed neither a DR-1 
site nor any other common cis elements, suggesting that dif-
ferent transcription factors regulate mttp versus mttp_v1. The 
lack of a TATA box in the promoter sequence, the relatively 
constant low level expression, and the absence of obvious cis-
elements imply that mttp_v1 is part of the TATA-boxless 
housekeeping gene family (46). In contrast, human mtp, 
which is transcribed from a single promoter, is not expressed 
in resting PBMCs but is strongly up-regulated in response to 
mitogenic stimuli. The human hepatoma cell line HepG2 
expresses high levels of mtp but down-regulates mtp tran-
scription in response to infl   ammatory signals such as LPS 
and IL-1 (39) or PHA and PMA/ION treatment, as shown 
in this study. Infl  amation-induced MTP down-regulation in 
hepatocytes presumably accounts for the presence of hepatic 
  steatosis in many infl   ammatory conditions of human liver 
(39). Thus, tissue-specifi  c regulation of MTP is achieved by 
alternate promoters in the mouse and by cell-type–specifi  c 
transcription factors, such as hepatocyte nuclear factor–4, in 
humans (47).
Hepatocytes and IECs likely produce both MTP tran-
scripts, but until now no group has detected mttp_v1 from 
these tissues, presumably because of the much higher abun-
dance of mttp (48). The MTPMx1 knockout mouse and an 
intestinal-specifi  c MTP knockout mouse show severe defects 
in VLDL and chylomicron secretion, respectively (34, 49). 
Because these mice still express mttp_v1, it is possible that 
MTPv1 cannot compensate for the loss of MTP with respect 
to lipoprotein production. Given that MTPv1 can support 
apoB secretion as effi   ciently as MTP when overexpressed, 
the most likely explanation for the MTPMx1 phenotype is 
that hepatocytes and IECs do not express trace amounts of 
MTPv1 protein and that the low level expression of MTPv1 
compared with MTP is insuffi   cient to rescue apoB secretion 
in the MTPMx1 mouse.
MTP and CD1d are highly conserved across species. We 
previously reported that rat MTP can lipidate mouse CD1d (33); 
we now show that mouse MTP lipidates mouse and human 
CD1d. In preliminary assays, bovine MTP is also capable of 
transferring lipid to mouse CD1d (unpublished data), an im-
portant point for future studies because bovine MTP can be 
obtained commercially and in large quantities.
Table II.  MFI of CD1d on FTOC cells
FTOC culture CD1d on 
total FTOC cells
CD1d on 
CD4+CD8+ subset
DMSO 20.9 ± 5.2 36.0 ± 3.7
BMS 212122 12.8 ± 2.7 (0.04) 37.0 ± 13.7 (NS)
BMS 200150 18.7 ± 4.2 (NS) 38.1 ± 1.2 (NS)
9-FL 19.7 ± 2.6 (NS) 38.1 ± 2.2 (NS)
MFI of CD1d on total FTOC cells from wild-type fetal thymic lobes cultured with the 
indicated compounds. Results are averaged from four independent experiments ± SD. 
The numbers in parentheses indicate p-values versus DMSO controls.
Table III.  Thymic subsets in FTOCs treated with MTP inhibitor compounds
CD4+CD8+ CD4+ CD8+
DMSO 20.4% 15.1% 33.8%
BMS212122 4.8% (0.025) 29.9% (0.05) 21.9% (0.13)
BMS200150 20.2% (0.97) 19.5% (0.41) 29.3% (0.37)
9-FL 18.4% (0.76) 14.9% (0.98) 34% (0.97)
Values are the average percent yield from six independent FTOC cultures. The numbers in parentheses indicate p-values versus DMSO controls.542  MTPV1 IN NKT CELL DEVELOPMENT | Dougan et al.
MTP is presumed to load the fi  rst endogenous lipid into 
the CD1d groove. This initial lipid antigen could be responsi-
ble for the selection of diverse NKT cells, as this population of 
NKT cells is unaff  ected by alterations in CD1d traffi   cking to 
endolysosomes, indicating that ER-derived lipids are suffi   cient 
for selection (30, 31). Lysosomal lipid transfer proteins act on 
CD1d by editing the lipid antigen. We propose that, in the ab-
sence of MTP function, the CD1d groove is collapsed or con-
tains a lipid refractory to editing. Thus, without MTP function, 
saposins and other lipid transfer proteins in the endosomal 
pathway are disabled in their ability to transfer lipid to CD1d.
CD1d has a remarkable ability to escape ER quality con-
trol mechanisms and can be expressed on the cell surface in 
the absence of β2-microglobulin or calnexin (50, 51). MTP 
inhibition in primary APCs and hepatocytes causes a modest 
decrease in surface CD1d, but MTP-inhibited CD1d trans-
fectants show no decrease in surface protein despite marked 
defects in CD1d antigen presentation (32, 33). The MTP in-
hibitor BMS200150 had no eff  ect on either the number of 
double-positive cells or CD1d surface expression on FTOC 
cells. The profound block in NKT cell development is there-
fore not caused by a quantitative lack of CD1d molecules but 
rather by a qualitative diff  erence in the lipid ligand or struc-
tural folding of the CD1d groove. Similar observations were 
made in both AP-3–defi  cient mice and in mice lacking the 
lipid storage protein Niemann-Pick type C1; although thy-
mocyte CD1d surface expression was unaff  ected or increased 
in these mice, NKT cells failed to develop (24, 27).
MTP is a critical chaperone and lipid transfer protein for 
CD1d in both mice and humans (32, 33). MTP activity in 
APCs is required for NKT cell activation, and we have now 
shown that MTP lipid transfer in thymocytes is required for 
NKT cell development. NKT cells play a causal role in many 
diseases, including asthma, autoimmune hepatitis, and in-
fl  ammatory bowel disease (52–55). Understanding how MTP 
contributes to NKT cell activation and development may 
provide insight into possible therapies for these diseases.
MATERIALS AND METHODS
Animals. Mice with two fl  oxed mttp alleles were bred with mice transgenic for 
Lck promoter–driven Cre recombinase (Jackson ImmunoResearch Laboratories) 
to generate MTPlck mice (34). C57BL/6J animals (Jackson Immuno-
Research Laboratories) were used as wild-type controls. All animal experimen-
tation was done in accordance with institutional guidelines and the review 
board of Harvard Medical School, which granted permission for this study.
Antibodies and reagents. Cells were stained with the following reagents: 
FITC-conjugated anti-CD3 (2C11; BD Biosciences), FITC-conjugated 
anti-CD4 (H129.19; BD Biosciences), PE-conjugated anti-CD8 (ly 3.2; BD 
Biosciences), PE-conjugated CD1d (1B1; BD Biosciences), PE-conjugated 
CD1d tetramer loaded with α-galcer (National Institutes of Health [NIH] 
Tetramer Facility), and PE-conjugated anti-CD69 (H1.2F3; BD Bio-
sciences). Staining was performed in the presence of Via-Probe (BD Bio-
sciences) and analyzed with a fl  ow cytometer (FACSort; Becton Dickinson). 
Cells were cultured with 5 μg/ml PHA (Sigma-Aldrich), 25 ng/ml PMA 
(Sigma-Aldrich), 1 μg/ml ION (Sigma-Aldrich), 300 ng/ml LPS (Sigma-
Aldrich), 40 μg/ml pokeweed mitogen (Sigma-Aldrich), 0.012% wt/vol 
heat-killed Staphylococcus aureus (Calbiochem), 100 μg/ml polyinositic-
polycytodylic acid (Sigma-Aldrich), 1 μg/ml muramyl dipeptide (InvivoGen), 
fl  agellin (5 μg/ml, Invivogen), ODN1826 (0.5 μM, InvivoGen), 10 μg/ml 
peptidoglycan (Sigma-Aldrich), and 100 nM insulin (Sigma-Aldrich).
RACE PCR. Total RNA was isolated and quantifi  ed from mouse tissues or 
cell lines using TRIzol (Invitrogen). RNA was quantifi  ed, and 0.2–1 μg 
was used for 5′ or 3′ RACE–ready cDNA synthesis using a RACE cDNA 
amplifi  cation kit (SMART; CLONTECH Laboratories, Inc.). RACE pro-
ducts were amplifi  ed using: fi  ve cycles of 94°C for 30 s and 72°C for 3 min; 
fi  ve cycles of 94°C for 30 s, 70°C for 30 s, and 72°C for 3 min; and 25 cycles 
of 94°C for 30 s, 68°C for 30 s, and 72°C for 3 min. mttp-specifi  c primers 
were as follows: 5′ RACE, T  G  A  C  A  G  C  A  G  C  G  G  C  A  G  T  T  G  T  G  C  G  C  A  C  C  G  T  ; 
and 3′ RACE, A  T  G  C  C  T  T  G  C  T  T  C  C  C  G  A  A  G  G  C  A  T  C  C  C  G  C  T . Amplifi  ca-
tion products were visualized by agarose gel electrophoresis and ethidium 
bromide staining. DNA was purifi  ed from excised gel slices (QIAGEN), 
ligated into TOPO TA Cloning vector (Invitrogen), and used to transform 
bacteria (OneShot TOP10; Invitrogen). Plasmids were reisolated from bac-
terial cultures (QIAGEN) and sequenced.
Semiquantitative and real-time PCR. Total RNA was extracted from 
tissues and cell lines, and 1 μg RNA was used for cDNA synthesis. For semi-
quantitative RT-PCR, 5 μl of neat, 1:10 or 1:100 diluted cDNA was used 
per 25-μl PCR. MTP transcripts were amplifi  ed using the following primers: 
mttp exon 1 (forward primer located in exon 1), 5′-A  T  G  A  T  C  C  T  C  T  T  G  G  C  A-
G  T  G  C  T  T  -3′; mttp_v1 exon 1 (forward primer located in exon v1), 5′-G  G  T-
C  T  C  A  C  T  G  A  A  T  C  T  G  G  A  G  A  G  G  A  A  -3′; MTT1 (forward primer located in 
exon 9), 5′-G  G  A  C  T  T  T  T  T  G  G  A  T  T  T  C  A  A  A  A  G  T  G  A  C  -3′; and MTT2 (re-
verse primer located in exon 13), 5′-G  G  A  G  A  A  A  C  G  G  T  C  A  T  A  A  T  T  G  T  G  -3′. 
Beta-actin was amplifi  ed using the following primers: 5′-A  T  C  T  G  G  C  A  C  C-
A  C  A  C  C  T  T  C  T  A  C  A  T  T  G  A  G  C  T  G  C  G  -3′ and 5′-C  G  T  C  A  T  A  C  T  C  C  T  G-
C  T  T  G  C  T  G  A  T  C  C  A  C  A  T  C  T  G  C  -3′. For real-time PCR, the following 
primers were used: mouse MTP forward, 5′-G  T  G  G  A  G  G  A  A  T  C  C  T  G  A  T-
G  G  T  G  A  -3′; mouse MTP reverse, 5′-T  G  A  T  C  T  T  A  G  G  T  G  T  A  C  T  T  T  T  G-
C  C  C  -3′; mouse IL-2 forward, 5′-G  T  G  C  T  C  C  T  T  G  T  C  A  A  C  A  G  C  G  -3′; 
mouse IL-2 reverse, 5′-G  G  G  G  A  G  T  T  T  C  A  G  G  T  T  C  C  T  G  T  A  -3′; human 
MTP forward, 5′-T  G  T  G  G  C  C  T  T  A  C  T  A  T  G  G  A  G  G  A  A  -3′; human MTP 
reverse, 5′-A  A  G  G  A  G  C  G  T  A  G  G  T  C  T  T  T  G  C  A  G  -3′; human IL-2 for-
ward, 5′-T  C  C  T  G  T  C  T  T  G  C  A  T  T  G  C  A  C  T  A  A  G  -3′; human IL-2 reverse, 
5′-C  A  T  C  C  T  G  G  T  G  A  G  T  T  T  G  G  G  A  T  T  C  -3′; 18S RNA forward, 5′-G  A  G-
G  G  A  G  C  C  T  G  A  G  A  A  A  C  G  G  -3′; and 18S RNA reverse, 5′-G  T  C  G  G  G  A  G  T-
G  G  G  T  A  A  T  T  T  G  C  -3′. Real-time PCR was performed using SYBR green 
(BioRad Laboratories) and 40 cycles of 94°C for 30 s, 60°C for 30 s, and 
72°C for 30 s. Final PCR amplifi  cation products were subjected to agarose gel 
electrophoresis and ethidium bromide staining to confi  rm product size.
Northern blotting. PCR products corresponding to mttp and mttp_v1 
(primers MTT1 and MTT2; 699-bp amplicon), mttp_v1 (primers alt1F and 
alt1R [5′-G  T  A  G  G  A  A  G  G  A  G  T  A  A  C  A  G  C  A  C  G  G  C  A  -3′]; 207-bp ampli-
con), or mttp (primers orig1Fb [5′-G  C  A  G  A  G  G  G  A  G  C  C  A  G  C  A  T  G  A  T  C  C  T-
C  T  T  G  G  C  -3′] and orig1R [5′-T  G  A  G  A  G  G  C  C  A  G  T  T  G  T  G  T  G  A  C  -3′]; 
96-bp amplicon) were labeled with 50 μCi [32P]dCTP (Redivue nucleo-
tides; GE Healthcare) using a labeling kit (DecaPrime II; Ambion). North-
ern blotting was performed using Northern Max (Ambion), according to the 
manufacturer’s instructions. In brief, total RNA samples were loaded in trip-
licate on a formaldehyde agarose gel, electrophoresed, transferred by down-
ward capillary transfer to a nylon membrane (Brightstar; Ambion), and UV 
cross-linked. Radiolabeled probes were denatured and hybridized to the 
membranes at 42°C in buff  er (UltraHyb; Ambion) for 16 h; washed twice in 
2× SSC, 0.1% SDS at room temperature; washed twice in 0.1× SSC, 0.1× 
SDS at 42°C; and exposed to fi  lm (BioMax MS; Kodak).
Cell lines and retroviral constructs. Cells were maintained in DMEM-10 
(2 mM l-glutamine, 10% fetal bovine serum) unless otherwise indicated. 
MODE-K, a mouse IEC line, has been previously described (56). DN32.D3 
(termed DN32 in these studies), a mouse Vα14Jα18 invariant TCR-positive 
T cell hybridoma, was provided by A. Bendelac (University of Chicago, JEM VOL. 204, March 19, 2007  543
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Chicago, IL [57]). The autoreactive mouse Vα14Jα18 invariant TCR-positive 
hybridoma 24.8 was provided by S. Behar (Brigham and Women’s Hospital, 
Boston, MA [22, 58]). RMAS is a previously described TAP-defi  cient mouse 
T cell lymphoma (59); RAW is an Abelson virus–transformed mouse macro-
phage cell line (American Type Culture Collection); and HepG2 is a human 
hepatoma cell line (American Type Culture Collection). COS-7 cells were 
purchased from the American Type Culture Collection. Ld is a previously 
described fi  broblast cell line transfected with the pSRαCD1d plasmid (60). 
MTP and MTPv1 sequences were cloned into pMFG and used to transfect 
the packaging cell line 293GPG, as previously described (61, 62). 293GPG 
and pMFG were provided by R. Mulligan (Children’s Hospital, Boston, 
MA) and G. Dranoff   (Dana Farber Cancer Institute, Boston, MA). MTP-
FLAG and MTPv1-FLAG vectors were produced by PCR with a 3′ anti-
sense primer encoding the FLAG sequence (DYKDDDDK), followed by an 
in-frame termination codon. Stably transduced cell lines were generated by 
three rounds of infection with transfected 293GPG culture supernatants.
Immunofl  uorescence. Ld cells transduced with MTP-FLAG or MTPv1-
FLAG were grown at low density on glass coverslips in 24-well plates. Cells 
were fi  xed and permeabilized in methanol for 15 min at −20°C. The fi  xed 
cells were blocked with PBS containing 1 mM MgCl2, 0.5 mM CaCl2, 3% 
BSA, and 1% goat serum and incubated with antibodies diluted 1:100 (unless 
stated otherwise) in the same buff  er at room temperature for 1 h. The cells 
were incubated with mouse anti-FLAG M2 (Sigma-Aldrich) and either rab-
bit anti-calnexin (StressGen Biotechnologies) or anti-PDI (1:50; StressGen 
Biotechnologies), followed by treatment with Alexa Fluor 488 (green 
  fl  uorescence)–conjugated goat anti–rabbit IgG1 and Alexa Fluor 594 (red 
fl  uorescence)–conjugated goat anti–mouse IgG1 (Invitrogen). The coverslips 
were mounted in phosphate-buff  ered saline containing 10% glycerol and 12% 
triethyldiamine (Sigma-Aldrich), to prevent fl  uorescent bleaching, and visu-
alized using a confocal microscope (Radiance 2000; Bio-Rad Laboratories).
FLAG purifi  cation and SDS-PAGE. MTP-FLAG– and MTPv1-FLAG–
expressing cells were washed three times in cold PBS, once in buff  er K (1 mM 
Tris, pH 7.4, 1 mM MgCl2, 1 mM EGTA, and complete protease inhibitor 
cocktail; Roche), and lysed by collecting cells in buff  er K with a cell scraper, 
followed by repeated passage through a 30-gauge needle. Lysates were 
  centrifuged to remove debris, and the salt concentration was increased to 
10 mM Tris, pH 7.4, 150 mM NaCl. Lysates were incubated with M2 resin 
(Sigma-Aldrich) for 4–6 h at 4°C. Proteins were eluted with FLAG peptide 
(Sigma-Aldrich), and an aliquot of each preparation was subjected to SDS-
PAGE, followed by Coomassie blue staining.
Triglyceride and PE transfer assays. The lipid transfer assay using NBD-
labeled triglyceride or NBD-labeled PE embedded in donor phospholipid ves-
icles (Chylos Inc.) has been previously described (40, 41). PE transfer to CD1d 
has also been previously described (33). In brief, black, high binding microtiter 
plates (Costar) were coated overnight at 4°C with 2 μg BSA, 0.0125 mol of 
recombinant protein G (Pierce Chemical Co.) and/or 0.025 mol/well of re-
combinant mouse CD1d (NIH Tetramer Facility), mouse CD1d-Fc (DimerX; 
BD Biosciences), mouse MHC class I–Fc (DimerX; BD Biosciences), or 
  human CD1d-Fc (DimerX; BD Biosciences). Wells were washed three times 
with PBS. FLAG-tagged MTP or MTPv1, and PE vesicles containing 6:1 
PE/NBD-PE were resuspended in transfer buff  er (1 mM Tris-HCl, pH 7.4, 
0.2 mM EDTA, 15 mM NaCl, 0.1% fatty acid–free BSA; Sigma-Aldrich), added 
to the wells, and incubated at 37°C for 2.5 h. Wells were then washed three 
times with PBS, and 100 μl isopropanol was added to each well and incubated 
for 2 min at room temperature. Fluorescence was read with a fl  uorescence 
plate reader using 485-nm excitation and 550-nm emission wavelengths.
ApoB secretion assay. COS-7 and Ld cells grown in DMEM-10 (2 mM 
l-glutamine, 10% fetal bovine serum) were stably transduced with retrovi-
ruses encoding MTP or MTPv1. The cells were initially dislodged from the 
plate with trypsin and seeded in six-well plates (400,000 cells/well). Trans-
fection of an apoB48 plasmid was performed using a transfection reagent 
(FuGENE 6; Roche). At 48 h after transfection, the media was aspirated, and 
1 ml of lipid-containing medium (DMEM including 0.4 mM oleic acid 
complexed with 1.5% BSA and 1 mM glycerol) was added. ApoB concen-
tration was measured by ELISA of 24-h culture supernatants. Protease inhib-
itors (Sigma-Aldrich) were added to culture supernatants before ELISA.
FTOC. Embryonic day 16 fetal thymic lobes were harvested from timed 
pregnant C57BL/6J or CD1d−/− mice and cultured as previously described, 
with minor modifi  cations (16). Three to six fetal thymic lobes per well were 
cultured on nitrocellulose fi  lters (Whatman) placed on a sponge (Gelfoam 
size 4; Upjohn Pharmacia). Lobes were cultured for 18–20 d in 3 ml DMEM 
containing 20% fetal bovine serum per well on six-well tissue culture plates. 
0.1% DMSO, 13 μM BMS212122 dissolved in DMSO (provided by 
R. Gregg, Bristol-Myers Squibb, Princeton, NJ), 10 μM BMS200150 dissolved 
in DMSO (provided by R. Gregg), or 13 μM 9-FL dissolved in DMSO 
(Sigma-Aldrich) was added to the media throughout the culture period. 
Media was changed every 3–4 d. Cells were harvested by mechanical disrup-
tion of the thymic lobes and passage through a 70-μm cell strainer. FTOC 
cells were resuspended in fresh media containing no MTP inhibitors and 
cultured in 96-well plates coated with 10 μg/ml anti-CD3 (2C11; BD 
Biosciences). IL-4 concentration was determined by ELISA of 48-h culture 
supernatants. A portion of the FTOC cells were used for fl  ow cytometry 
and/or RNA isolation.
Statistics. The Student’s t test was used to determine signifi  cance.
Online supplemental material. Fig. S1 shows that MTP inhibitors 
BMS212122 and BMS200150 block MTPv1-mediated phospholipid trans-
fer. Fig. S2 shows a representative FACS plot of CD4 and CD8 thymocyte 
subsets in MTP inhibitor–treated FTOCs, as well as the CD1d surface 
  expression on each subset. Online supplemental material is available at 
http://www.jem.org/cgi/content/full/jem.20062006/DC1.
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